Our results demonstrate for the first time that a peripheral blood-derived biomarker (PD-L1+ PMN frequency) could independently predict patient clinical outcome to nivolumab in BRAF wild type melanoma patients, providing an additional tool for therapeutic choices in clinical oncology. Here, BRAF is linked to melanoma.